Basel’s cannabis pilot now has a usable market signal: lower-risk formats took 18% share without lifting purchases
New data from Basel-Stadt’s Weed Care trial shows that cannabis oil, vapes and spray quickly reached about 18% of monthly purchase volume while per-person purchasing stayed stable, giving Europe one of its clearest early readings on how a tightly regulated adult-use market may actually behave.
Read more
